PARP INHIBITOR
Clinical trials for PARP INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PARP INHIBITOR trials appear
Sign up with your email to follow new studies for PARP INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug shows promise in early trial for Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SPR1020 in 210 adults with advanced solid tumors that have not responded to standard treatments. The drug aims to shrink tumors by targeting a specific DNA repair pathway, and may also work in the brain. The main goals are to find the safest dos…
Matched conditions: PARP INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:15 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, vismodegib and atezolizumab, in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can shrink tumors or slow disease prog…
Matched conditions: PARP INHIBITOR
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated May 26, 2026 08:07 UTC
-
New telehealth program aims to ease fatigue in ovarian cancer patients
Symptom relief Recruiting nowThis study tests a telehealth program called REVITALIZE to see if it can lessen how much fatigue interferes with daily life for people with advanced ovarian cancer who are taking PARP inhibitors. About 240 adults will be randomly assigned to either the REVITALIZE program or recei…
Matched conditions: PARP INHIBITOR
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated May 22, 2026 13:54 UTC